行情

ACER

ACER

Acer Therapeutic
NASDAQ

实时行情|Nasdaq Last Sale

3.380
+0.020
+0.60%
交易中 12:10 09/18 EDT
开盘
3.350
昨收
3.360
最高
3.420
最低
3.330
成交量
2.57万
成交额
--
52周最高
31.99
52周最低
1.871
市值
3,412.17万
市盈率(TTM)
-1.0690
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ACER 新闻

  • Bragar Eagel & Squire is Investigating Certain Officers and Directors of Mammoth Energy, Acer Therapeutics, Realogy Holdings, and AxoGen and Encourages Investors to Contact the Firm
  • GlobeNewswire.6天前
  • Acer Therapeutics: Undervalued With A Free Call Option On EDSIVO
  • Seeking Alpha - Article.09/05 12:51
  • Shareholder Alert: Robbins Arroyo LLP Reminds Investors Acer Therapeutics Inc. (ACER) Sued for Misleading Shareholders
  • Business Wire.08/30 18:02
  • FINAL DEADLINE - Acer Therapeutics Inc. (ACER) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: August 30, 2019
  • ACCESSWIRE.08/30 15:04

更多

所属板块

生物技术和医学研究
-1.08%
制药与医学研究
-0.26%

热门股票

名称
价格
涨跌幅

ACER 简况

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
展开

Webull提供Acer Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。